Senti Biosciences, Inc. (SNTI) Stock Forecast
SNTI analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.50 / 5 from 2 analysts
- Price target
- $13.50 average of analyst targets
- Upside to target
- +5,900.0% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.38
- 52-week range
- $0.23 – $2.39
SNTI analyst ratings
2 analystsNumber of analysts at each rating.
SNTI price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
SNTI earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.29 | −$0.38 | −$0.21 | −$0.69 | +57.2% | 2 |
| Current fiscal year (2026) | −$1.04 | −$1.31 | −$0.78 | −$2.73 | +61.7% | 2 |
| Next fiscal year (2027) | −$0.95 | −$0.96 | −$0.94 | −$1.04 | +9.1% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
SNTI revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 2 |
| Current fiscal year (2026) | $50,000 | $0 | $100,000 | +127.3% | 2 |
| Next fiscal year (2027) | $50,000 | $0 | $100,000 | 0.0% | 2 |
SNTI EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
SNTI revenue: reported and forecast
SNTI EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.32 | −$0.38 | −$0.38 | −$0.38 | −$0.29 | −8.8% | 0 up · 0 down |
| Current fiscal year (2026) | −$1.09 | −$1.16 | −$1.16 | −$1.16 | −$1.04 | −4.4% | 0 up · 0 down |
| Next fiscal year (2027) | −$0.90 | −$0.95 | −$0.95 | −$0.95 | −$0.95 | +6.1% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
SNTI earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; SNTI beat in 3 of 9.
What analysts expect from SNTI
2 analysts cover Senti Biosciences; their consensus rating is strong buy (4.50 on a 1–5 scale, where 5 is a strong buy). The average price target is $13.50, 5,900.0% above the latest close of $0.23. Analysts expect earnings of −$1.04 per share for 2026, +61.7% from a year earlier. For 2027 the average estimate is −$0.95 per share on revenue of $0.1 million. Senti Biosciences beat the EPS estimate in 3 of the last 9 quarters.
Related: SNTI income statement, SNTI key metrics, SNTI chart. See the SNTI stock overview for the latest quote and news.
SNTI forecast FAQ
What is Senti Biosciences's price target?
The average analyst price target for Senti Biosciences is $13.50, 5,900.0% above the latest close of $0.23.
Is Senti Biosciences a buy, hold or sell?
Of 2 analysts covering Senti Biosciences, 1 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Senti Biosciences's EPS forecast?
Analysts forecast −$1.04 per share for 2026 (range −$1.31 to −$0.78); for 2027 the estimate is −$0.95.
What is Senti Biosciences's revenue forecast?
The average revenue estimate for 2026 is $0.1 million, growth of 127.3%; for 2027 it is $0.1 million.
When does Senti Biosciences report earnings?
Senti Biosciences is expected to report results for the quarter ending September 30, 2026 on November 12, 2026; the EPS estimate is $-0.38.
Does Senti Biosciences usually beat earnings estimates?
Senti Biosciences reported EPS at or above the analyst estimate in 3 of the last 9 quarters.